26718-25-2
Chemical Structure
Halofenate
Synonym(s): MK 185
- CAS No.: 26718-25-2
- Formula:C19H17ClF3NO4
- Molecular Weight:415.79
IUPAC Name: 2-acetamidoethyl 2-(4-chlorophenyl)-2-(3-(trifluoromethyl)phenoxy)acetate
InChIKey: BJBCSGQLZQGGIQ-UHFFFAOYSA-N
SMILES: CC(NCCOC(C(C1=CC=C(Cl)C=C1)OC2=CC=CC(C(F)(F)F)=C2)=O)=O
Biological Activity: Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Halofenate | Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
